Get started
Author

Christian Meyer zum Bueschenfelde

Observed names: C. M. yer Zum Bueschenfelde, C. M. z. Bueschenfelde, C. Meyer Zum Bueschenfelde, C. Meyer zum Bueschenfelde, C. Meyer zum Büchenfelde, C.M. zum Büschenfelde, Ch. Meyer zum Büschenfelde, Christian Meyer Zum Bueschenfelde, Christian O Meyer zum Bueschenfelde
Observed institutions: TUM Klinikum, Yale University, St. Vincentius-Kliniken, Asklepios, Asklepios Kliniken Hamburg, Technical University of Munich
OpenAlex ID: A5060484128
Regulated Recruitment of MHC Class II and Costimulatory Molecules to Lipid Rafts in Dendritic Cells
2004 · Christian O Meyer zum Bueschenfelde, Julia Unternaehrer, et al. · The Journal of Immunology · 48
Somatic hypermutation analysis in follicular lymphoma provides evidence suggesting bidirectional cell migration between lymph node and bone marrow during disease progression and relapse
2013 · M. Wartenberg, P. Vasil, et al. · Haematologica · 39
PDF
Antifungal Therapy with Itraconazole Impairs the Anti-Lymphoma Effects of Rituximab by Inhibiting Recruitment of CD20 to Cell Surface Lipid Rafts
2010 · Ingo Ringshausen, Yvonne Feuerstacke, et al. · Cancer Research · 15
PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): The MUNICON-II study.
2011 · F. Lordick, C. Meyer Zum Bueschenfelde, et al. · Journal of Clinical Oncology · 6
1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial
2023 · F. Bozorgmehr, E.L. Buchmeier, et al. · Annals of Oncology · 5
PDF
Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial
2025 · Jochen Gaedcke, Malte Sahrhage, et al. · Scientific Reports · 4
Thoracic radiotherapy PLUS durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy: Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy—The TRADE-hypo trial.
2021 · Farastuk Bozorgmehr, Jessica Juergens, et al. · Journal of Clinical Oncology · 4
Adoptiver Transfer von malignomreaktiven T-Zellen
1999 · H. Bernhard, Ch. Meyer zum Büschenfelde, et al. · Der Onkologe · 2
1021P DURATION - a phase II randomized trial in older / frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): Top-line early efficacy endpoints
2022 · J.B. Kuon, M. Blasi, et al. · Annals of Oncology · 1
GM1 Expression of Non-Hodgkins Lymphoma Determines Susceptibility to Rituximab Treatment.
2007 · Christian Meyer zum Bueschenfelde, Yvonne Feuerstacke, et al. · Blood · 1
Modified CARG Score-Guided First-Line Treatment in Older or Vulnerable Patients With Advanced Non-Small-Cell Lung Cancer: Results of the Randomized, Phase 2 DURATION Trial (AIO-YMO/TRK-0416)
2026 · J. Kuon, M. Blasi, et al. · Clinical Lung Cancer
272eP Interim data on neoadjuvant nivolumab plus platinum-based chemotherapy (neoadj NIVO+CT) in patients (pts) with non-metastatic resectable NSCLC from the non-interventional study (NIS) NENI
2026 · C. Meyer zum Bueschenfelde, M. Reiser, et al. · ESMO Open
PDF
Antifungal Therapy with Itraconazole Impairs Rituximab′s Anti-Lymphoma Effect by Inhibiting CD20 Recruitment to Lipid Rafts.
2009 · Christian Meyer zum Bueschenfelde, Yvonne Feuerstacke, et al. · Blood
Induction of a cellular immune response against the tumor-associated antigen HER-2/neu using retrovirally transduced dendritic cells
1999 · C. M. yer Zum Bueschenfelde, Nicole Nicklisch, et al.
Works count: 14
Citation count: 125
H-index: 5
I10-index: 3
Year
Topic
Type